Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Decline in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 28,906 shares, a decrease of 51.7% from the September 15th total of 59,859 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 160,909 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating. According to data from MarketBeat, Fresenius SE & Co. has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

Shares of OTCMKTS:FSNUY traded up $0.13 during midday trading on Thursday, reaching $12.47. The company’s stock had a trading volume of 774,592 shares, compared to its average volume of 171,606. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $33.93. The company has a market capitalization of $28.09 billion, a P/E ratio of 15.78 and a beta of 0.60. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The business’s fifty day simple moving average is $13.06 and its 200-day simple moving average is $12.35.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. The company had revenue of $6.91 billion for the quarter, compared to analyst estimates of $6.65 billion. As a group, equities research analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.